[Bevacizumab administered along with chemotherapy results in an improvement in the overall survival in women with advanced breast cancer].
Svoboda
M
M
Klinika komplexní onkologické péce, Masarykův onkologický ústav, Brno. msvoboda@mou.cz
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D015996:Survival Rate
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab